{"title":"美容整形手术中抗血小板和抗凝治疗的管理：文献综述。","authors":"Federico Taraschi, Chiara Botti, Giovanni Botti","doi":"10.1007/s00266-025-04943-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The perioperative management of anticoagulant and antiplatelet therapy in aesthetic plastic surgery is a critical challenge, especially with the increasing demand for cosmetic procedures among elderly patients. Currently, there is a notable lack of consensus in the available literature regarding the optimal perioperative management of these medications in elective aesthetic procedures.</p><p><strong>Methods: </strong>A systematic review of PubMed, Embase, and Cochrane Library databases was conducted up to September 2024 to identify studies addressing anticoagulant and antiplatelet therapy management in aesthetic plastic surgery. Inclusion criteria focused on studies related to perioperative management and bleeding risks in elective cosmetic procedures. Articles unrelated to aesthetic surgery or written in non-English languages were excluded.</p><p><strong>Results: </strong>From 192 identified studies, 10 were included. Recommendations varied by procedure and patient risk. For high-risk surgeries like facelifts, anticoagulant cessation 48-72 h before surgery was advised. For low-risk procedures like blepharoplasty, continuation of antithrombotics was deemed safe in some cases, but consensus was lacking.</p><p><strong>Discussion: </strong>The review highlights a lack of standardization in managing anticoagulant and antiplatelet therapies in aesthetic surgery. There is an urgent need for risk-based guidelines to ensure patient safety and minimize bleeding and thromboembolic risks.</p><p><strong>Conclusion: </strong>The management of anticoagulant and antiplatelet therapy in aesthetic plastic surgery remains uncertain. Given the elective and aesthetic nature of these procedures, patient safety should always take precedence.</p><p><strong>Level of evidence iv review: </strong>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .</p>","PeriodicalId":7609,"journal":{"name":"Aesthetic Plastic Surgery","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of Antiplatelet and Anticoagulant Therapy in Aesthetic Plastic Surgery: A Literature Review.\",\"authors\":\"Federico Taraschi, Chiara Botti, Giovanni Botti\",\"doi\":\"10.1007/s00266-025-04943-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The perioperative management of anticoagulant and antiplatelet therapy in aesthetic plastic surgery is a critical challenge, especially with the increasing demand for cosmetic procedures among elderly patients. Currently, there is a notable lack of consensus in the available literature regarding the optimal perioperative management of these medications in elective aesthetic procedures.</p><p><strong>Methods: </strong>A systematic review of PubMed, Embase, and Cochrane Library databases was conducted up to September 2024 to identify studies addressing anticoagulant and antiplatelet therapy management in aesthetic plastic surgery. Inclusion criteria focused on studies related to perioperative management and bleeding risks in elective cosmetic procedures. Articles unrelated to aesthetic surgery or written in non-English languages were excluded.</p><p><strong>Results: </strong>From 192 identified studies, 10 were included. Recommendations varied by procedure and patient risk. For high-risk surgeries like facelifts, anticoagulant cessation 48-72 h before surgery was advised. For low-risk procedures like blepharoplasty, continuation of antithrombotics was deemed safe in some cases, but consensus was lacking.</p><p><strong>Discussion: </strong>The review highlights a lack of standardization in managing anticoagulant and antiplatelet therapies in aesthetic surgery. There is an urgent need for risk-based guidelines to ensure patient safety and minimize bleeding and thromboembolic risks.</p><p><strong>Conclusion: </strong>The management of anticoagulant and antiplatelet therapy in aesthetic plastic surgery remains uncertain. Given the elective and aesthetic nature of these procedures, patient safety should always take precedence.</p><p><strong>Level of evidence iv review: </strong>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .</p>\",\"PeriodicalId\":7609,\"journal\":{\"name\":\"Aesthetic Plastic Surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aesthetic Plastic Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00266-025-04943-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aesthetic Plastic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00266-025-04943-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Management of Antiplatelet and Anticoagulant Therapy in Aesthetic Plastic Surgery: A Literature Review.
Background: The perioperative management of anticoagulant and antiplatelet therapy in aesthetic plastic surgery is a critical challenge, especially with the increasing demand for cosmetic procedures among elderly patients. Currently, there is a notable lack of consensus in the available literature regarding the optimal perioperative management of these medications in elective aesthetic procedures.
Methods: A systematic review of PubMed, Embase, and Cochrane Library databases was conducted up to September 2024 to identify studies addressing anticoagulant and antiplatelet therapy management in aesthetic plastic surgery. Inclusion criteria focused on studies related to perioperative management and bleeding risks in elective cosmetic procedures. Articles unrelated to aesthetic surgery or written in non-English languages were excluded.
Results: From 192 identified studies, 10 were included. Recommendations varied by procedure and patient risk. For high-risk surgeries like facelifts, anticoagulant cessation 48-72 h before surgery was advised. For low-risk procedures like blepharoplasty, continuation of antithrombotics was deemed safe in some cases, but consensus was lacking.
Discussion: The review highlights a lack of standardization in managing anticoagulant and antiplatelet therapies in aesthetic surgery. There is an urgent need for risk-based guidelines to ensure patient safety and minimize bleeding and thromboembolic risks.
Conclusion: The management of anticoagulant and antiplatelet therapy in aesthetic plastic surgery remains uncertain. Given the elective and aesthetic nature of these procedures, patient safety should always take precedence.
Level of evidence iv review: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
期刊介绍：
Aesthetic Plastic Surgery is a publication of the International Society of Aesthetic Plastic Surgery and the official journal of the European Association of Societies of Aesthetic Plastic Surgery (EASAPS), Società Italiana di Chirurgia Plastica Ricostruttiva ed Estetica (SICPRE), Vereinigung der Deutschen Aesthetisch Plastischen Chirurgen (VDAPC), the Romanian Aesthetic Surgery Society (RASS), Asociación Española de Cirugía Estética Plástica (AECEP), La Sociedad Argentina de Cirugía Plástica, Estética y Reparadora (SACPER), the Rhinoplasty Society of Europe (RSE), the Iranian Society of Plastic and Aesthetic Surgeons (ISPAS), the Singapore Association of Plastic Surgeons (SAPS), the Australasian Society of Aesthetic Plastic Surgeons (ASAPS), the Egyptian Society of Plastic and Reconstructive Surgeons (ESPRS), and the Sociedad Chilena de Cirugía Plástica, Reconstructiva y Estética (SCCP).
Aesthetic Plastic Surgery provides a forum for original articles advancing the art of aesthetic plastic surgery. Many describe surgical craftsmanship; others deal with complications in surgical procedures and methods by which to treat or avoid them. Coverage includes "second thoughts" on established techniques, which might be abandoned, modified, or improved. Also included are case histories; improvements in surgical instruments, pharmaceuticals, and operating room equipment; and discussions of problems such as the role of psychosocial factors in the doctor-patient and the patient-public interrelationships.
Aesthetic Plastic Surgery is covered in Current Contents/Clinical Medicine, SciSearch, Research Alert, Index Medicus-Medline, and Excerpta Medica/Embase.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
